Pacira BioSciences Stock (NASDAQ:PCRX)


ForecastChart

Previous Close

$22.73

52W Range

$11.16 - $27.64

50D Avg

$24.88

200D Avg

$22.02

Market Cap

$1.05B

Avg Vol (3M)

$695.89K

Beta

0.51

Div Yield

-

PCRX Company Profile


Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

788

IPO Date

Feb 03, 2011

Website

PCRX Performance


Latest Earnings Call Transcripts


Q2 22Aug 03, 22 | 12:32 PM
Q1 22May 04, 22 | 1:23 PM
Q4 21Feb 24, 22 | 12:36 PM

Peer Comparison


TickerCompany
EVOEvotec SE
SUPNSupernus Pharmaceuticals, Inc.
IRWDIronwood Pharmaceuticals, Inc.
RAREUltragenyx Pharmaceutical Inc.
PBHPrestige Consumer Healthcare Inc.
COLLCollegium Pharmaceutical, Inc.
PTCTPTC Therapeutics, Inc.
ENTAEnanta Pharmaceuticals, Inc.